Literature DB >> 33280926

A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib.

Mengnan Li1, Qiusu Tang2, Songan Chen3, Yina Wang4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33280926     DOI： 10.1016/j.lungcan.2020.11.014

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  2 in total

1.  Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report.

Authors:  Xiaodong Gu; Wenxian Wang; Wei Wu; Yiping Zhang; Lan Shao; Mariacarmela Santarpia; Petros Christopoulos; Nathaniel J Myall; Zhiyong Shi; Guangyuan Lou
Journal:  Transl Lung Cancer Res       Date:  2022-05

2.  High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report.

Authors:  Yan Li; Peng Duan; Yan Guan; Qing Chen; Anna Grenda; Petros Christopoulos; Marc G Denis; Qisen Guo
Journal:  Transl Lung Cancer Res       Date:  2022-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.